topstockalerts
AstraZeneca is considering entering the cancer vaccine market, exploring one of oncology’s most active research areas as pharmaceutical companies investigate new ways to prevent tumors from returning and treat different forms of cancer. CEO Pascal Soriot told analysts at the European Society for Medical Oncology conference in Madrid that cancer vaccines have been the subject of extensive internal discussions.
Soriot said AstraZeneca’s research and development team has made significant progress in mRNA technology over the past several years, giving the company confidence that it could develop meaningful opportunities in the field. He added that further details could emerge over the coming months and years.
The British drugmaker has previous vaccine experience through its COVID-19 vaccine developed with Oxford University, although its core focus remains cancer treatments, cardiometabolic diseases and rare conditions.
$AZN
1
2

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F08%2F595.jpg)